Olympus Corporation of the Americas recalled 916 units of the EVIS EXERA III Bronchoscope BF-Q190 on September 11, 2025. The recall addresses safety concerns related to its use with laser and high-frequency therapy equipment. Healthcare providers must stop using the device immediately and follow recall instructions.
Additional IFU updates to provide further clarification on safe and effective use of bronchoscopes when used in conjunction with laser, argon plasma coagulation, and high-frequency therapy equipment.
Patients and healthcare providers should stop using this device immediately. Follow the recall instructions provided by the manufacturer. Contact Olympus Corporation of the Americas or your healthcare provider for instructions
The recalled product is the EVIS EXERA III Bronchoscope, model BF-Q190. It was distributed nationwide in the U.S. and there are 1,402 units recalled internationally. No pricing information was available.
The recall stems from additional updates to the Instructions for Use (IFU) relating to the safe and effective use of bronchoscopes with laser, argon plasma coagulation, and high-frequency therapy equipment. The potential for misuse could lead to serious health risks.
As of the recall date, there were no reported incidents, injuries, or deaths associated with this product. The high hazard level indicates significant concern, prompting the recall.
Stop using the bronchoscope immediately. Contact Olympus Corporation of the Americas or your healthcare provider for further instructions.
For more information, contact Olympus Corporation of the Americas at their official website or customer service.
Get notified about recalls in categories you care about.
Bristol-Myers Squibb recalled 12,778 vials of Opdualag injection on October 21, 2025. The recall stems from a lack of assurance of sterility. The affected products were distributed nationwide in the United States.
Major Pharmaceuticals recalled Gabapentin Capsules, USP, 100 mg, on October 10, 2025, due to failed impurities specifications. The recall affects several lot numbers distributed nationwide. Consumers must stop using the affected capsules immediately.
Lannett Company, Inc. recalled 46,848 bottles of Niacin Extended-release Tablets on October 10, 2025. The recall follows reports of failed dissolution specifications, which could affect medication effectiveness. Consumers should stop using the product immediately and consult healthcare providers for guidance.